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Abstract Conventional approaches for antiparasitic drug discovery center upon discovering
selective agents that adversely impact parasites with minimal host side effects. Here, we show that
agents with a broad polypharmacology, often considered ‘dirtier’ drugs, can have unique efficacy if
they combine deleterious effects on the parasite with beneficial actions in the host. This principle is
evidenced through a screen for drugs to treat schistosomiasis, a parasitic flatworm disease that
impacts over 230 million people. A target-based screen of a Schistosoma serotoninergic G protein
coupled receptor yielded the potent agonist, ergotamine, which disrupted worm movement. In
vivo, ergotamine decreased mortality, parasite load and intestinal egg counts but also uniquely
reduced organ pathology through engagement of host GPCRs that repressed hepatic stellate cell
activation, inflammatory damage and fibrosis. The unique ability of ergotamine to engage both
host and parasite GPCRs evidences a future strategy for anthelmintic drug design that coalesces
deleterious antiparasitic activity with beneficial host effects.
DOI: https://doi.org/10.7554/eLife.35755.001
Introduction
Schistosomiasis (infection with parasitic blood flukes) affects over 230 million people, with severe
infections causing ~200,000 deaths per year. Chronic infections are associated with morbidities
such as anemia, impaired cognitive development and stunted growth (Colley et al., 2014; King and
Dangerfield-Cha, 2008). Infection is acquired upon exposure to freshwater, larval cercariae which
penetrate the host skin. Inside host tissue, cercariae transform into schistosomula that access and
traverse the circulatory system, pass through the lungs and liver before finally residing as mature
adults within either the mesenteric vessels (Schistosoma mansoni and Schistosoma japonicum) or
vasculature surrounding the urinary bladder (Schistosoma haematobium) (Wilson, 2009;
Georgi et al., 1986). The sexually mature male and female worms pair up and generate a prodigious
number of eggs, depositing hundreds to thousands of eggs per female worm per day
(Cheever, 1969; Cheever et al., 1994; Barlow and Meleney, 1949). Eggs lodge within the perito-
neal organs, evoking a massive Th2 response which cues granuloma formation and consequent
pathology in affected organs (reviewed in [Cheever, 1969]). In the case of urogenital schistosomiasis
(S. haematobium infection) eggs are deposited in the bladder mucosa and urinary tract, resulting in
hematuria and increased rates of squamous-cell carcinoma. In the case of intestinal schistosomiasis
(S. mansoni and S. japonicum infections), eggs are deposited in the liver and hepatic portal system
leading to periportal fibrosis, pulmonary hypertension and ascites.
Broad spectrum chemotherapy of schistosomiasis relies upon praziquantel (PZQ), which has been
in clinical use for nearly 40 years (Colley et al., 2014; King and Dangerfield-Cha, 2008;
Andrews et al., 1983). Mass drug administration (MDA) programs will require ~250 million tablets
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of PZQ per year for at risk populations (Osakunor et al., 2018). The widespread distribution of schis-
tosomiasis, coupled with observations that PZQ can be subcurative in areas of high intensity of infec-
tion and transmission (Danso-Appiah and De Vlas, 2002; King et al., 2011) raise concerns that
treatment resistant parasites may emerge (Fallon and Doenhoff, 1994; Fallon et al., 1995;
Ismail et al., 1996; Wang et al., 2012). Therefore, it is important to identify new flatworm drug tar-
gets and lead compounds to expand the arsenal of drugs available to treat schistosomiasis and
other parasitic flatworm infections currently resolved through PZQ administration.
In this regard, targeting parasite neuromuscular physiology has proven to be a highly successful
anthelmintic approach (Geary et al., 1992). In schistosomes, serotonin (5-HT) controls motor func-
tion and a specific serotonergic G-protein coupled receptor (GPCR) mediating this effect has been
implicated by both RNAi (Patocka et al., 2014) and drug screening (Chan et al., 2016a,
2016b). Here, we cloned full-length 5-HT receptor sequences from each of three major species caus-
ing human infection worldwide and expressed these targets in a high-throughput capable assay
enabling screening of thousands of compounds from natural product libraries. The dataset identified
anti-schistosomal chemotypes that conveyed anti-parasitic efficacy. Most importantly these activities
led to the discovery that the ergot alkaloid ergotamine ameliorated both infection and the patholog-
ical sequelae of infection. These properties highlight an opportunity to combat schistosome infec-
tions and their pathological impact on the host using single agents that coalesce deleterious actions
on parasites with beneficial activities on host responses.
Results
Pharmacological profiling of a schistosome 5-HTR
Full-length sequences for a serotoninergic GPCR (5-HTR) were cloned from the three major schisto-
some species causing infections worldwide; Schistosoma mansoni (Sm.5HTRL[Chan et al., 2016b]),
S. haematobium (Sh.5HTR) and S. japonicum (Sj.5HTR). The three 5HTRs shared high amino acid sim-
ilarity (84–94%), and clustered with 5-HT7 receptors from other organisms (Figure 1—figure supple-
ments 1 and 2). In mammalian HEK293 cells, GFP-tagged variants of each 5-HTR localized at the cell
surface (Figure 1A), enabling functional profiling. To measure signaling output, GPCR activity was
eLife digest More than 200 million people worldwide are infected with parasitic worms that
cause the disease schistosomiasis. Most cases occur in sub-Saharan Africa. Long-term infections can
damage organs, and children who are affected may suffer delayed growth and learning difficulties.
Despite its significant health and economic impact, schistosomiasis is still considered a ‘neglected’
tropical disease. This means there has not been adequate investment into developing new
treatments or cures.
A drug called praziquantel is currently the only treatment for schistosomiasis. However, the drug
has unpleasant side effects, cannot cure all infected individuals, and there is a concern that worms
may develop resistance to its effects. This means there is an urgent need to develop new therapies.
One possible approach would be to develop drugs that interfere with the worm’s ability to move.
Chan et al. screened thousands of existing chemicals for interactions with a protein that is known
to control how the worms move. A drug called ergotamine, which is currently used to treat
migraines, strongly interacted with the protein. Treating infected mice with ergotamine eliminated
the parasites and reduced the organ damage caused by the infection. Praziquantel also reduced the
number of parasites in the mice but it did not prevent organ damage.
The results presented by Chan et al. show that a single drug can interact with targets in both the
worm and the animals it infects. Searching for drugs that have this dual effect may help to develop
more effective treatments for schistosomiasis and other diseases caused by parasites. Ergotamine
itself is unlikely to be used to treat people for schistosomiasis because of the side effects produced
when using it repeatedly. However, these findings will help researchers identify and develop safer
drugs with similar benefits.
DOI: https://doi.org/10.7554/eLife.35755.002
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assessed using a luciferase based cAMP reporter (GloSensor 22F, Promega) engineered to undergo
a conformational change on cAMP binding that increases luciferase activity (Figure 1B). The choice
of this reporter was guided by prior evidence demonstrating coupling of the flatworm SER-7 GPCRs
to Gs (Patocka et al., 2014; Chan et al., 2016b, 2016c) and the ability of this approach to resolve
real time kinetics of cAMP generation with high sensitivity in intact cells. The 5-HTRs from each
Figure 1. Functional expression of Schistosoma serotonin receptors. (A) Confocal images showing cell surface expression in mammalian HEK293 cells
of 5-HT receptors cloned from S. mansoni (Sm.5HTRL), S. haematobium (Sh.5HTR) and S. japonicum (Sj.5HTR) localized by COOH-terminally tagged
eGFP. Scalebar, 50 mm. (B) Schematic of luminescent cAMP sensor bioassay. cAMP generated by schistosome 5-HTRs (blue) binds the engineered
GloSensor luciferase, switching the sensor to a more active conformation resulting in enhanced luminescence output. (C) Kinetics of signal following the
addition of 5-HT (1 mM) to HEK293 cells co-transfected with luminescent cAMP sensor and individual schistosome 5-HT receptors. Open circles, cells
not transfected with 5-HT receptor, colored circles represent measurements in cells transfected with Sm.5HTRL (black), (Sh.5HTR (blue) and Sj.5HTR
(red). (D) Serotonin dose-response curves for each of the three receptors (colored circles) and HEK293 cells expressing the cAMP sensor alone (open
circles). Data reflect mean ± standard error of at least 3 biological replicates.
DOI: https://doi.org/10.7554/eLife.35755.003
The following figure supplements are available for figure 1:
Figure supplement 1. Schistosome 5-HT receptor protein alignment.
DOI: https://doi.org/10.7554/eLife.35755.004
Figure supplement 2. Cladogram of schistosome 5-HT receptors.
DOI: https://doi.org/10.7554/eLife.35755.005
Figure supplement 3. Performance of the Sm.5HTRL luminescent cAMP reporter assay.
DOI: https://doi.org/10.7554/eLife.35755.006
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individual schistosome species were transiently transfected into a stable HEK293 cell line expressing
the cAMP reporter and luminescence values monitored during addition of 5-HT. Each of the GPCRs
responded to the addition of 5-HT with a rapid elevation in luminescence values (~70–110 fold
increase, Figure 1C) with sensitivity in the low nanomolar range for Sj.5HTR and Sh.5HTR
(EC50 = 3.0 ± 0.3, 3.6 ± 0.3 nM) and 76 ± 1 nM for Sm.5HTRL (Figure 1D). To facilitate high-through-
put drug screening of these targets, dual stable cell lines expressing both the cAMP reporter and
individual 5-HTR clones were derived and individual lines evaluated based on performance in a 384-
well format. Conditions were iterated to deliver robust resolution of the signals elicited by 5-HT
(‘agonist screen’, Z’ score >0.7, signal window >10) and the known inhibitory action of bromocriptine
(‘antagonist screen’, Z’ score >0.6, Figure 1—figure supplement 3), a previously identified antago-
nist (Chan et al., 2016b).
Having optimized these methods, we proceeded to screen the S. mansoni 5HTRL against a com-
pilation of natural product libraries (4288 compounds, Supplementary file 1). The screening proto-
col consisted of an ‘agonist screen’ (addition of compound alone, 10 mM) followed by an ‘antagonist
screen’ (inhibition of response to 5-HT, 1 mM) in the same cells for every compound. The workflow,
and criteria for putative ‘hit’ designation, from the primary screen are shown in Figure 2A. An exam-
ple of the data profile generated for a putative agonist ‘hit’ and an antagonist ‘hit’ is shown in
Figure 2B.
Compilation of the screening dataset is shown in Figure 2C, where the fold-increase (‘agonist
screen’) or decrease (relative to 5-HT, ‘antagonist screen’) in luminescence values are plotted for
individual compounds. From the whole dataset (4288 ligands), 92 putative hits were identified that
exceeded threshold criteria (Figure 2C). These compounds were then counter-screened against the
parental HEK293 reporter cell line lacking any schistosome 5-HTR (Figure 2D). This was necessary to
exclude false positive hits, for example compounds that stimulated cAMP production through
endogenous HEK293 targets (GPCRs, direct adenylate cyclase activators), or compounds that non-
specifically inhibited cAMP production. Counter-screening triaged 40 of the original 92 hits, invalid-
ating compounds that either stimulated cAMP production or inhibited forskolin-evoked cAMP gen-
eration in cells lacking Sm.5HTRL. Overall, the screening dataset yielded 52 compounds (12 agonists
and 40 antagonists at Sm.5HTRL, ~1.2% hit rate) for subsequent investigation. Chemotype analysis
of the ‘hit’ compounds (Figure 2E) revealed two main groups of favored structures. The first core
group of ligands were benzylisoquinolines with aporphine or protoberberine cores. These com-
pounds were exclusively antagonists. The second group of compounds contained an indole ring sys-
tem, either bicyclic tryptamines, or ergot alkaloids with a four ring ergoline core. This second group
of compounds comprised both agonist and antagonist ligands. This range of efficacies underpinned
prioritization of these ligands, and ergot alkaloids as the predominant chemotype, for further analy-
sis of the structure-activity relationship at the parasitic 5-HTRs.
Structural determinates of activity at schistosome 5-HTRs
Ergot alkaloids are a diverse group of compounds with a long history of therapeutic use. Their inter-
action with mammalian bioaminergic GPCRs encompasses a range of activities and kinetic profiles
(Knight et al., 2009; Wacker et al., 2017). Based on the results from the natural product screen, an
expanded series of ergot alkaloid ligands was sourced for structure-activity screening (‘SAR by com-
merce’). Complete dose-response relationships were performed for twenty compounds containing
the tetracyclic ergoline skeleton (5 compounds from the primary screen plus 15 commercially
sourced ligands) against all three schistosome 5.HTRs (Sm.5HTRL, Sh.5HTR and Sj.5HTR).
Ergot alkaloid interactions with the schistosome 5-HTRs spanned a range of effects. To summarize
these actions, agonist efficacy (relative to peak levels of 5-HT evoked cAMP generation) and antago-
nist potency (pKi) were represented as heat-maps where increasingly intense coloration represents
higher efficacy (Figure 3A) and potency (Figure 3B). Several features of this dataset merit comment.
First, these representations convey a shared responsiveness across the three 5-HTRs to tested
ligands, suggesting a conservation of pharmacological profile between the 5-HTR orthologs from
the different schistosome species. This is important if any putative lead compounds are to be broad
spectrum, that is effective against each of the major infective strains. Second, the data evidence a
broad spectrum of potencies and efficacies within the ergot alkaloid series evidencing full agonists
(for example, compound ‘1’ ergotamine, ‘2’ dihydroergotamine), partial agonists (compound ‘3’,
lisuride), antagonists (compounds ‘16’ terguride, ‘19’, bromocriptine, ‘20’ 2-bromo-LSD) as well as
Chan et al. eLife 2018;7:e35755. DOI: https://doi.org/10.7554/eLife.35755 4 of 25
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Figure 2. High-throughput screen of natural product libraries against Sm.5HTRL. (A) Assay workflow for drug screen. Compounds were screened
against HEK293 cells stably expressing a cAMP sensor and Sm.5HTRL, followed by counter-screening hits against a cell line lacking Sm.5HTRL. (B)
Kinetic readout of luminescence from cAMP biosensor following addition of (i) test compound (10 mM, open arrow; agonist hits increase luminescence),
followed by (ii) the addition of 5-HT (1 mM, solid arrow; antagonist hits decrease luminescence relative to controls). (C) Scatter plot of compounds
Figure 2 continued on next page
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closely related ‘inactive’ compounds (compound ‘14’, a-ergocryptine). Third, marked changes in effi-
cacy and inhibitory potency resulted from minimal structural modifications to the core scaffold. For
example, hydrogenation of the D9-10 double bond of lisuride (compound ‘3’) eliminated efficacy to
yield the antagonist terguride (compound ‘16’, IC50 = 400 ± 50 nM, Figure 3C). The partial agonist
LSD (compound ‘6’) is converted into a potent antagonist (IC50 = 100 ± 20 nM) on bromination at
the B2 indol ring position (2-Bromo-LSD, compound ‘20’). Distinct structural modifications impacting
efficacy could be seen in an ergopeptine series (Figure 3D), through comparison of the chemical
structures of ergotamine (compound ‘1’), a potent full agonist at each schistosome receptor (Emax95
± 4, 96 ± 5 and 114 ± 3% of 5-HT for Sm.5HTRL, Sh.5HTR and Sj.5HTR, respectively), the inactive a-
ergocryptine (compound ‘14’) and bromocriptine (compound’ 19) which acted as a potent blocker
(IC50 = 1.6 ± 0.4 mM) of Sm.5HTRL (Figure 3D). Such SAR data underscore the potential for modify-
ing the ergoline scaffold to maximize, or engineer away, efficacy at schistosome 5HTRs
(Figure 3C and D).
Overall, structure-activity analysis across the three schistosome 5-HTRs identified ergotamine
(compound ‘1) as the most potent, full agonist and 2-Bromo-LSD (compound ‘20’) as the most
potent antagonist for further evaluation.
Validation of Sm.5HTRL ligands on schistosomes ex vivo
The effects of prioritized compounds from the screen were examined on the movement of adult par-
asites cultured ex vivo. Male and female worms respond to 5-HT with increased movement
(Figure 4A). This responsiveness permits the basic screening assay shown in Figure 4B, where
changes in worm motility are resolved in response to compound addition, and in the presence of 5-
HT. For example, 5-HT (200 mM) increased worm movement, and 5-HT stimulation was not observed
following preincubation with bromocriptine (1 mM, Figure 4B). Compounds that exhibited agonist
activity at each of the three 5-HTRs in vitro also stimulated worm movement ex vivo (Figure 4C).
While the rank order of potency varied slightly from the in vitro screen, an increase in potency of
ergot alkaloids relative to 5-HT was evident (EC50 for 5-HT = 51.6 ± 3.0 mM, EC50 = 97.8 ± 31.6 nM
for ergotamine, EC50 = 1.4 ± 0.5 mM for LSD). As expected, the potent antagonist BOL-148
(Figure 3C) blocked 5-HT evoked hyperactivity (Figure 4D). BOL-148 displayed ~10 fold higher
potency than bromocriptine consistent with the results from the in vitro screen (IC50 = 28.8 ± 23.1
nM for BOL-148 versus IC50 = 331 ± 271 nM for bromocriptine, Figure 4D).
Antischistosomal action of Sm.5HTRL ligands in vivo
Do these schistosome 5-HTR ligands display anthelmintic activity in vivo? As processes such as para-
site feeding, mate pairing and movement within the host vasculature depend upon coordinated neu-
romuscular function, exposure to ligands that stimulate hyperactivity (5-HTR agonists) or cause
paralysis (5-HTR antagonists) may promote dysfunction and parasite clearance.
One indicator of acute drug efficacy that may prove indicative of anthelmintic activity is a shift in
location of the parasites from the mesenteric vessels to the liver (the ‘hepatic shift’), where worms
are subsequently targeted for elimination by the host immune system (Buttle and Khayyal, 1962;
Pellegrino et al., 1977; Mehlhorn et al., 1981). To examine the ability of the prioritized 5-HT
ligands to cause this hepatic shift, mice harboring a mature schistosome infection (42 days p.i.) were
given 5-HTR ligands by intraperitoneal injection and sacrificed three hours later to assess parasite
distribution (Figure 5A). Numbers of worms residing within the mesenteries, portal vein or liver
were assessed. Following treatment with PZQ (100 mg/kg), most of the worms were found within
the liver (68.8 ± 14.1% of recovered parasites, Figure 5B), whereas worms were infrequently found
Figure 2 continued
assaying for (i) agonists and (ii) antagonists. Putative hits surpassing threshold are shown in color (blue, agonists; red, antagonists). (D) Counter-screen
of putative hit compounds from (C) against cell lines lacking 5-HT receptor to exclude compounds with off-target increases in cAMP (top) or
compounds that reduce forskolin (25 mM) evoked cAMP signals (bottom). (E) Hits clustered into compound classes by structure. Groups contain
common ring systems such as benzylisoquinoline (ex. 1. ST059293, 2. Nantenine, 3. 785163, 4. Nuciferine, 5. Remerine) or indole (6. Ergotamine, 7.
Metergoline, 8. Nicergoline, 9. N-methylserotonin, 10. 5-bromotryptamine) structures. Blue = agonists, red = antagonists.
DOI: https://doi.org/10.7554/eLife.35755.007
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Figure 3. Structure activity relationship of ergot alkaloid compounds. Ergot alkaloids display a spectrum of activity against Schistosoma 5-HT receptors
ranging from (A) agonists (expressed as maximal cAMP response relative to 5-HT) to (B) antagonists (estimated receptor affinity expressed as pKi). (C)
Structure activity relationship within a lysergic acid amide series. Derivatives of the partial agonist LSD displayed modified activity following
modification of the diethylamide moieties (Danso-Appiah and De Vlas, 2002; Fallon and Doenhoff, 1994; Cheever, 1969; Wilson, 2009) or the
Figure 3 continued on next page
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within the liver in mice injected with vehicle control (9.7 ± 8.5% of recovered parasites). The perfor-
mance of a selection of 5-HTR agonists or antagonists was then benchmarked relative to these
standards.
Treatment with 5-HTR agonists elicited a hepatic shift (Figure 5B). However, treatment with 5-
HTR antagonists did not alter worm distribution (Figure 5B). Furthermore, the extent of the hepatic
shift observed in mice treated with 5-HTR agonists correlated with the measured efficacy of these
agonists at the parasite 5.HTR (Figure 5B). Full agonists promoted the greatest shift: for example,
ergotamine treatment of mice yielded a similar percentage of worms in the liver (75.1 ± 16.9%) as
seen in mice treated with PZQ. Partial agonists promoted a lesser response, and 5-HTR antagonists
were ineffective. For example, neither bromocriptine (2.0 ± 2.8% of worms in liver) or BOL-148 (5.2 ±
2.3% of worms in liver) caused a hepatic shift of worms (Figure 5B) despite the effectiveness of these
compounds at arresting worm movement ex vivo (Figure 4D). Based on these data, we prioritized
treatment of infected mice with ergotamine to assess amelioration of chronic schistosomiasis.
In vivo efficacy of ergotamine
Mice were injected with vehicle control (DMSO), PZQ (50 mg/kg) or ergotamine (60 mg/kg) twice
daily for one week starting 42 days post infection (p.i.). Control animals succumbed to infection (~8–
10 weeks p.i.) over a timeframe consistent with the onset of egg laying by sexually mature parasites
as expected (Figure 6A, [Cheever, 1969]). By 15 weeks p.i., the majority of control mice were dead.
Death rates were significantly reduced in ergotamine-treated mice (16.5% versus 68.9% mortality in
control cohort, log-rank test p<0.001, hazard ratio 5.02). PZQ-treated mice survived through 15
weeks with no observed lethality (Figure 6A).
As ergotamine increased survival of infected mice, we assessed various metrics of infection (worm
burden, egg number, hepatosplenomegaly) immediately following ergotamine treatment (42–49
days p.i). First, ergotamine treatment significantly reduced worm burden from 28 ± 8 worm pairs per
mouse to 9 ± 6 worm pairs per mouse (~65% reduction, p<0.002; Figure 6B). Next, egg counts
were performed. Eggs deposited within the mesenteric system progress through the intestinal
mucosa for excretion from the host, thereby propagating the parasite life cycle (Pellegrino and
Faria, 1965). Therefore, it is possible to determine whether drug treatment impacted parasite egg
laying by counting eggs in sections of the large and small intestines. Control mice contained large
numbers of viable eggs in both the small and large intestine. However, treatment with either ergota-
mine or PZQ resulted in a considerable reduction (96.3 ± 1.2 and 99.9 ± 0.1%, respectively) in intesti-
nal egg burden (Figure 6C). We also assessed whether serotonergic manipulation influenced egg
laying in worms cultured ex vivo (Figure 6—figure supplement 1A). Egg laying was decreased fol-
lowing treatment with ergotamine (1 mM, 54.2 ± 12.6% reduction), serotonin (100 mM, 82.4 ± 2.2%
reduction) or forskolin (100 mM, 61.6 ± 12.6% reduction) (Figure 6—figure supplement 1B&C).
Eggs laid by ergotamine treated worms were often small and deformed, indicating abnormal devel-
opment (Figure 6—figure supplement 1D). We conclude ergotamine was highly effective at block-
ing parasite egg production and development.
Next, liver and spleen sizes were measured. A consequence of the enormous production of schis-
tosome eggs is a host Th2 wave (Grzych et al., 1991) that drives granuloma formation and fibrosis
in affected peritoneal organs (Pearce and MacDonald, 2002). Hepatosplenomegaly is a hallmark of
chronic schistosomiasis and splenomegaly and liver fibrosis are observed in the murine model (Fal-
lon, 2000). This is reflected by comparison of the weights of uninfected mouse spleens (0.12 ± 0.02
g) and the spleens of infected littermates (~6 fold enlargement, weighing 0.76 ± 0.20 g at 49 days p.
i), or increases in liver mass (~2 fold enlargement from 2.0 ± 0.3 g in uninfected mice to 4.8 ± 0.8 g
Figure 3 continued
ergoline ring system (Geary et al., 1992; Chan et al., 2016c). (D) Structure activity relationship within a ergopeptine chemical series. Derivatives of the
full agonist ergotamine with altered activity following modification of the tripeptide structure (Barlow and Meleney, 1949; Andrews et al., 1983;
Ismail et al., 1996) or the ergoline ring system (Chan et al., 2016b). Compound numbering reflects rank order of efficacy across the schistosome 5-
HTRs: 1. Ergotamine; 2. Dihydroergotamine; 3. Lisuride; 4. 6-NOR LSD; 5. Methylergometrine; 6. LSD; 7. Dihydroergocristine; 8. Dihydroergotoxine; 9.
Pergolide; 10. LAMPA; 11. Elmoclavine; 12. Ergonovine; 13. Nicergoline; 14. a-ergocryptine; 15. Mesulergine; 16. Terguride; 17. LY215840; 18.
Metergoline; 19. Bromocriptine; 20. BOL-148. Data represent mean ± standard error of at least three biological replicates.
DOI: https://doi.org/10.7554/eLife.35755.008
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in infected mice, Figure 6D). PZQ treatment (one week, starting at 42 days p.i) did not prevent
spleen and liver enlargement (Figure 6D). There was no difference in the weights of the liver and
spleen between PZQ-treated and vehicle treated infected mice (Figure 6E and F). This is likely due
to the fact that, while PZQ is highly effective at eliminating worms at six weeks infection and beyond
Figure 4. Ergot alkaloid action against adult S. mansoni parasites ex vivo. (A) Serotonin induced increase in movement of S. mansoni adult male (M,
solid circles) and female (F, open circles) parasites. (B) Adult S. mansoni movement in the absence of drug (black trace), following 5-HT addition (200
mM, blue), or exposure to a Sm.5HTRL antagonist (BOL-148, 1 mM) and subsequent 5-HT (200 mM, red) addition. (C) Dose-response curves for Sm.5HTRL
agonist evoked stimulation of adult schistosome movement. Ergot alkaloids = solid symbols, 5-HT = open blue circles. (D) Dose-response curves for
Sm.5HTRL antagonist inhibition of 5-HT (200 mM) evoked movement. Worm movement data (A, C–D) reflect mean ± standard error of the mean for at
least 3 biological replicates.
DOI: https://doi.org/10.7554/eLife.35755.009
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Figure 5. Ergot alkaloid agonists evoke an acute hepatic shift of parasites in vivo. (A) Location of mouse vasculature dissected after drug treatment to
resolve worm location. Adult parasites normally reside in the mesenteric vasculature (i), but following anthelmintic treatment shift to the portal vein (ii)
and liver (iii). (B) Left, quantification of percent worm burden found in either the mesenteries, portal vein or liver following treatment with DMSO
Figure 5 continued on next page
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(Sabah et al., 1986; Keiser et al., 2009), sexual maturation and egg laying commence as early as 5
weeks post infection (Sabah et al., 1986), meaning that eggs deposited prior to treatment initiation
still evoke an immune response which PZQ exposure does not ameliorate. In contrast to PZQ, ergot-
amine exposure prevented hepatosplenomegaly. Ergotamine reduced the infection-promoted
increase in spleen mass by 55.8 ± 14.0% and liver mass by 52.0 ± 14.2% relative to vehicle treated
controls (Figure 6E and F). Similarly, liver sections from ergotamine-treated infections displayed
decreased granuloma formation and fibrosis when investigated by various staining methods
(Figure 6G and Figure 6—figure supplement 2). Movat’s stain and Masson’s trichrome showed
decreased levels of collagen deposition surrounding granulomas (Figure 6G,II–III). Aldehyde fuchsin
stain showed elastin surrounding the granulomas of DMSO and PZQ treated mice, while the livers of
uninfected or ergotamine treated mice exhibited little staining (Figure 6G,IV). Oil red O staining
revealed lipid stores present in the livers of uninfected mice that were absent in infected control liv-
ers. Treatment with ergotamine, but not PZQ, preserved regions of Oil red O positive staining -
albeit at lower levels than healthy livers (Figure 6G,V). Pro-apoptotic cleaved caspase-3 was present
in cells within granulomas of all three infected livers (DMSO control, ergotamine and PZQ treated –
Figure 6G,VI).
Finally, we tested whether ergotamine displayed efficacy as a treatment against immature infec-
tions, where PZQ is ineffective (Sabah et al., 1986). Both 5-HT and ergotamine stimulated move-
ment of juvenile worms ex vivo (Figure 6—figure supplement 3A and B). In vivo, however, early
dosing with ergotamine prior to egg laying (3–4 weeks post infection) did not resolve infections, mir-
roring the lack of effect of PZQ (Figure 6—figure supplement 3C).
In conclusion, these data show that ergotamine was highly effective at promoting survival in mice
with mature infections (Figure 6A) through reductions in worm (Figure 6B) and egg number
(Figure 6C). However - unlike PZQ - ergotamine was effective at attenuating hepatosplenomegaly
associated with the chronic pathology of schistosomiasis.
Ergotamine impairs activation of hepatic stellate cells
How does ergotamine treatment protect against hepatosplenomegaly resulting from schistosome
infection? Both ergotamine and PZQ clear parasites, but unlike ergotamine, PZQ-treated mice did
not show a noticeable difference in liver and spleen size relative to control infections (Figure 6). As
ergotamine is a human therapeutic with affinity for various host GPCRs (O’Connor and Roth, 2005),
in addition to high affinity for schistosome 5-HT receptors (Figure 3D), engagement of host signal-
ing pathways likely underpins these protective effects.
To investigate mechanisms contributing to the differential in vivo effects of these drugs, we per-
formed RNA-Seq analyses on the livers and spleens of schistosome-infected mice following drug
treatment (PZQ, ergotamine) over a window 6 to 7 weeks post-infection (Figure 7A). Livers and
spleens of infected mice showed widespread changes in gene expression relative to uninfected lit-
termates; of the 24,421 transcripts with mapped sequencing reads, 9684 transcripts were differen-
tially expressed in infected livers and 7325 transcripts were differentially expressed in infected
spleens. It is well established that the host pathology of schistosomiasis infection is driven by an ini-
tial Th1 response to the worms themselves followed by a sustained Th2 response that drives egg-
induced fibrosis (reviewed in [Pearce and MacDonald, 2002; Wynn et al., 2004]). Such a gene
expression signature has been observed in numerous studies on livers or spleens of infected mice
(Sandler et al., 2003; Burke et al., 2010; Gobert et al., 2015; Perry et al., 2011) and is borne out
here through our data comparing infected and uninfected controls. Most components of Th1 and
Th2 signaling pathways were significantly changed in both infected livers and spleens relative to
uninfected littermates (Figure 7B and C).
Drug treatment with either PZQ or ergotamine attenuated transcriptional changes associated
with infection. The identity of transcripts changing with drug treatment (either with PZQ or with
Figure 5 continued
(negative control), praziquantel (100 mg/kg, positive control) and various ergot alkaloid compounds. Diameter of circle represents proportionality of
distribution. Right, bar chart represents efficacy of the same series of compounds at Sm.5HTRL.
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Figure 6. Ergotamine resolves infections and mitigates pathology of schistosomiasis in vivo. (A) Survival of mice infected with S. mansoni and treated
for one week (days 42–49 post infection) with either vehicle control (DMSO. n = 26 mice), ergotamine (ERG, 60 mg/kg twice daily. n = 22 mice) or
praziquantel (PZQ, 50 mg/kg daily. n = 10 mice). (B) Worm burden of mice treated as in A and sacrificed 49 days post-infection. (C) Intestinal egg
counts of mice sacrificed in B. (D) Representative livers and spleens from uninfected mice and infected mice exposed to vehicle (DMSO), ergotamine
Figure 6 continued on next page
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ergotamine treatment versus control infections) largely overlapped with those changing with infec-
tion (uninfected animals versus control infections) but as expected drug-treatment was associated
with a decrease of transcripts up-regulated in control infections (relative to uninfected animals) or an
increase of transcripts down-regulated in control infections (relative to uninfected animals,
Figure 7D). Specifically, PZQ or ergotamine treatment decreased expression of pathways associated
with host immune response to either parasites (acute phase response signaling, Th1 and Th2 path-
way) or bacteria entering the circulation with the breakdown of the intestinal epithelium that occurs
with heavy parasite egg production ultimately leading to host death (LPS/IL-1 mediated inhibition of
RXR function [Feingold et al., 2004; Wang et al., 2005]). Expression of pathways associated with
drug metabolism (xenobiotic metabolism signaling) and liver function (hepatic cholestasis) increased
with both treatments (Figure 7D). These observations that the PZQ and ergotamine cohorts shared
similar transcriptional patterns relative to control infection is consistent with both treatments resolv-
ing infection and parasite egg production (Figure 6B and C).
Next, we sought to filter the transcriptomic dataset to identify transcriptional changes unique to
ergotamine treatment (Figure 7E). This involved selecting transcripts that (i) displayed significant
changes between uninfected and control infection cohorts, and (ii) were differentially expressed
between control infection and ergotamine-treated cohorts, and (iii) showed little change between
control infection and praziquantel treated cohorts (Figure 7E). Ingenuity pathway analysis using this
triple-filtered criteria identified a cohort of transcripts uniquely associated with ergotamine, but not
PZQ, treatment. These transcripts were tagged for involvement in hepatic fibrosis and hepatic stel-
late cell (HSC) activation (p-value 0.00015, Fisher’s exact test). Ergotamine treatment down-regu-
lated gene products associated with HSC activation to control infections, while PZQ treatment had
little to no effect on the same suite of transcripts. HSCs represent a quiescent, non-proliferative cell
population in normal liver but once activated during injury or disease, drive fibrotic responses by
transforming into proliferative, contractile myofibroblasts that deposit extracellular matrix compo-
nents (Tsuchida and Friedman, 2017). Differentially expressed transcripts in ergotamine-treated
samples (Supplementary file 4) included known markers of HSC activation responsible for extracel-
lular matrix production (COL1A1, COL1A2, COL3A1), transcripts associated with HSC contraction
(CACNA1E, CACNA1H), migration (IGFBP3, RANTES), survival (IGFBP5, GAS6) and transdifferentia-
tion into myofibroblasts (MMP13, GLI1, PAK1) (Figure 7F and G). Ligands that control HSC activa-
tion and survival were also differentially expressed (PDGFB, IL13RA2, BMP4, IL-4, SAA).
Therefore, ergotamine and PZQ were both effective at promoting survival (Figure 6A) through
reductions in worm (Figure 6B) and egg number (Figure 6C), as well as reversing many transcrip-
tional signatures that drive host pathological outcomes in response to parasite infection (Figure 7D).
However, unlike PZQ, ergotamine was also effective at attenuating the hepatosplenomegaly associ-
ated with the chronic pathology of schistosomiasis (Figure 6D–G), due to decreased activation of
profibrotic HSCs (Figure 7E–G).
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(ERG) or praziquantel (PZQ). Quantification of hepatomegaly (E) and splenomegaly (F) in uninfected mice (open columns) and infected mice following
drug treatment (solid columns). (G) Histology of liver sections control uninfected and infected (DMSO) mice, as well as drug treated (ERG and PZQ)
infected animals (scale = 1 mm). Liver histology using (I) H and E staining, (II) Movat’s stain (collagen, yellow), (III) Masson’s trichrome stain (collagen,
blue), (IV) aldehyde fuchsin stain (elastin, purple), (V) Oil red O stain (lipid, red), and (VI) caspase-3 activation (brown puncta, arrows). Higher
magnification images of egg granulomas for each staining condition are shown in Figure 6—figure supplement 2.
DOI: https://doi.org/10.7554/eLife.35755.011
The following figure supplements are available for figure 6:
Figure supplement 1. Ergotamine inhibition of S. mansoni egg laying during ex vivo culture.
DOI: https://doi.org/10.7554/eLife.35755.012
Figure supplement 2. Liver egg granulomas in control and drug treated mice.
DOI: https://doi.org/10.7554/eLife.35755.013
Figure supplement 3. Effects of ergotamine on immature S. mansoni.
DOI: https://doi.org/10.7554/eLife.35755.014
Figure supplement 4. Lack of hepatic microvesicular steatosis in drug treated livers.
DOI: https://doi.org/10.7554/eLife.35755.015
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Figure 7. Effect of ergotamine on immune response and hepatic stellate cell activation. (A) Schematic of schistosome infection and drug treatment
cohorts analyzed. Livers and spleens were harvested from infected mice treated with vehicle control, ergotamine (ERG 60 mg/kg, twice daily for 7 days)
or praziquantel (PZQ 50 mg/kg, once daily for 5 days), as well as uninfected littermate controls. Five mice were used per cohort. (B) Volcano plots
showing transcriptional changes of the liver and spleens from infected mice compared to uninfected littermates. Green shading highlights gene
Figure 7 continued on next page
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Discussion
Given the importance of serotonergic signaling in parasite physiology, the possibility of serotonergic
drugs providing effective antiparasitic agents has long been recognized (Mansour, 1979). With a
defined molecular target (a prevalent schistosome 5-HTR cloned from each of the main species that
cause schistosomiasis) and an optimized functional profiling assay for this GPCR (Figure 1), we have
now been able to investigate this possibility. Here, we screened thousands of compounds in vitro
(Figure 2) and interpolated structure-activity studies on promising chemical series (Figure 3). These
cell-based assays yielded candidates for ex vivo screening against adult parasites (Figure 4), and
thereby prioritization of the most active compounds for in vivo testing in a mouse model of schisto-
somiasis (Figure 5). This pipeline identified unique properties of ergotamine, an ergot alkaloid first
isolated 100 years ago (Hofmann, 1978) and FDA-approved medication for migraine, for treating
schistosomiasis. Ergotamine increased survival in a murine model of schistosomiasis through reduc-
tions in parasite burden and resultant egg load, but most intriguingly resolved inflammatory damage
caused by schistosome eggs laid in host tissues, an effect not observed with PZQ under the same
conditions (Figure 6). These effects likely result from the broad polypharmacology of ergotamine
that coalesces a fortuitous combination of effects at both host and parasite GPCRs.
Action on parasite
Ergotamine is a potent Sm.5HTRL agonist (Figure 3). Sm.5HTRL and homologs of this receptor in
other flatworms, regulate movement (Patocka et al., 2014; Chan et al., 2015). Sm.5HTRL is downre-
gulated upon pairing of adult S. mansoni females and males, implicating an additional role in sexual
maturation (Lu et al., 2016). As a Gs coupled receptor, the role of 5-HT acting through cAMP to reg-
ulate flatworm metabolism is also relevant (Mansour, 1984). These broad physiological roles - motor
function, female egg production, metabolism – underscore consideration of Sm.5HTRL as an attrac-
tive antischistosomal target. Screening hits (Figure 2), and subsequent structure-activity studies (Fig-
ure 3) confirmed the ergoline core as a customizable scaffold for ligand optimization at Sm.5HTRL.
These analyses provided a toolbox of compounds with varied potencies and efficacies against
Sm.5HTRLin vitro and Sm.5HTRL agonists and antagonists stimulated and inhibited adult worm motil-
ity ex vivo as predicted (Figure 4). However in vivo, only agonists of Sm.5HTRL signaling caused a
hepatic shift of worms and mitigated worm burden, Sm.5HTRL blockers were ineffective (Figure 5).
This observation was surprising given the presumed beneficial effect of causing potent (BOL-148) or
long-lasting (bromocriptine) worm paralysis (Chan et al., 2016a, 2016c), but nevertheless informa-
tive for future phenotypic screens to prioritize ‘hyperactive’ over ‘hypoactive’ serotoninergic hits.
From these analyses, ergotamine emerged as a potent full agonist (Figure 3D) that stimulated
movement ex vivo (Figure 4C) and reduced worm and disease burden in vivo (Figure 6).
Action on host
While ergotamine stimulates schistosome movement through 5.HTRs, the drug also acts on host
GPCR targets. Ergotamine is known to display a broad polypharmacology, interacting with numer-
ous bioaminergic GPCRs (O’Connor and Roth, 2005). These interactions likely engage physiological
responses that mitigate the damage caused by egg laying and possibly contribute to worm
Figure 7 continued
products involved in Th1/Th2 cell signaling. (C) Heat map of liver (L) and spleen (S) changes in Th1 and Th2 signaling pathways - color intensity
corresponds to significance (FDR adjusted p-values). (D–G) Effects of anthelmintics on hepatic gene expression of schistosome infected mice. (D) Top
left - differentially expressed transcripts comparing the livers of infected controls to uninfected littermates (grey), PZQ-treated animals (red) and ERG-
treated animals (blue). Top right - expression of transcripts either up-regulated or down-regulated in infected livers relative to uninfected livers (z
score 1 or  1) in control and drug treated animals. Bottom, transcripts differentially expressed between PZQ-treated or ERG-treated and control
infections represent pathways involved in liver function, drug metabolism and immune response. Ingenuity Pathway Analysis enrichment scores reflect -
log10 p-value of PZQ and ERG datasets (p-value 0.05 = -log10 1.3). (E) Filtering of transcripts changing with schistosomiasis infection that are affected by
ERG but not PZQ, resulting in an enrichment for gene products involved in hepatic fibrosis/HSC activation. (F) Role of various gene products in HSC
activation, and (G) read counts for these transcripts across uninfected (open box), infected (grey box) and ERG-treated (blue box) and PZQ-treated (red
box) cohorts. Box plots represent 25–75 percentile, whiskers 5–95 percentile. Inset; bar = median, square = mean. Read count data for liver and spleen
samples available in Supplementary files 2 and 3.
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elimination. Acutely, ergotamine acts as a vasoconstrictor, including within the mesenteric vascula-
ture where the adult worms reside (Mikkelsen et al., 1981). Disruption of the parasite environment
consequent to ergotamine-evoked mechanical changes and alterations of blood flow within the
hepatic portal system could drive parasites from the mesenteries to the liver for elimination. This
action would mirror recent data demonstrating R-PZQ, which also causes a hepatic shift, acts a
human 5-HT2B receptor partial agonist that contracts host mesenteric vessels (Chan et al., 2017).
Chronically, drug treatment with either PZQ or ergotamine improved various aspects of liver function
(hepatic cholestasis, retinol metabolism, bile acid synthesis, Figure 7D and Supplementary file 4)
relative to untreated infections. Beneficial changes highlighted by RNA-Seq also encompassed pro-
tection against intestinal damage (Cao et al., 2010). Various pathways involved in response to bac-
terial infection were down regulated with PZQ and ergotamine treatment relative to control
infections (Supplementary file 4). This is likely because mice experience a relative infection burden
orders of magnitude higher than typical for humans (Cheever, 1969) resulting in compromised intes-
tinal integrity and release of microbiota into the circulation as mature parasites commence egg pro-
duction. These effects likely contribute to the observed lethality post-infection and are shown to be
mitigated by both drug treatments in the RNA-Seq analysis.
However, ergotamine additionally provided protection against the spleen and liver enlargement
that persisted in PZQ-treated mice (Figure 6D and E), suggesting a further action of ergotamine on
the host immune response. Analysis of RNA-Seq datasets identified transcriptional changes unique
to ergotamine and not PZQ treatment, most notably a decrease in gene products involved in hepatic
fibrosis (Figure 7E–G). Hepatic stellate cells (HSCs) are key drivers of fibrosis during liver disease.
Upon their transformation into myofibroblasts, HSCs initiate active production of extracellular matrix
components (collagen, elastin – Figure 6G,II-IV) and decrease lipid storage (Figure 6G,V,
[Tsuchida and Friedman, 2017]). HSCs are known to express a portfolio of GPCRs that regulate acti-
vation and transformation (Tsuchida and Friedman, 2017). These include several serotonergic
GPCRs (5HT1B, 5HT1F, 5HT2A, 5HT2B, 5HT7, [Ruddell et al., 2006]). It is tantalizing that the known
polypharmacological signature of ergotamine (O’Connor and Roth, 2005) closely matches the sero-
toninergic GPCR expression profile in HSCs (Ruddell et al., 2006). This may imply a cell-autonomous
action of ergotamine on HSCs, although further insight would be needed to distinguish this possibil-
ity from non cell-autonomous mechanisms given that serotonin impacts immune responses and liver
regeneration in a multiplicity of ways (Herr et al., 2017; Lesurtel et al., 2006; Ebrahimkhani et al.,
2011). For example, ergotamine could impair HSCs indirectly by inhibiting macrophage polarization
(de las Casas-Engel et al., 2013) or immune mediators such as TNF-a and ICAM-1 (54). ICAM-1 is
found at elevated levels within egg-evoked granulomas (Ritter and McKerrow, 1996) and TNF-a
drives the host immune response to schistosome eggs (Amiri et al., 1992; Leptak and McKerrow,
1997). Prior studies on schistosome infection of immune compromised mice have shown that T-cell
deprived mice exhibit hepatic microvesicular steatosis, since granulomas also have a beneficial func-
tion of facilitating excretion of eggs from the mesenteries and sequestering toxic egg products
(reviewed in [Hams et al., 2013; Doenhoff et al., 1986]). Ergotamine treatment impaired the granu-
lomatous response to eggs (Figure 6G, Figure 6—figure supplement 2), but increased microvascu-
lar damage was not observed (Figure 6—figure supplement 4). Additional experiments will be
needed to investigate stellate cell responsiveness and whether ergotamine is effective against other
parasitic diseases currently treated with PZQ.
While the polypharmacology of ergotamine evidences the principle of combining host and para-
site responses for therapeutic effect, it is not itself a likely candidate for repurposing. Repeated dos-
ing of ergotamine as an antimigraine therapy is associated with known side effects: it is
contraindicated in pregnancy and poorly suited for the large pediatric population susceptible to
schistosomiasis. For future studies, analogs with improved pharmacokinetic profile and bioavailability
will need to be evaluated for clinical potential as safe and effective agents. Indeed, for treatment of
parasitic infections, a single bolus dose may provide more flexibility and avoid cumulative side
effects associated with repeated dosing. Our limited structural-activity studies to date (e.g. Figure 3)
on schistosome GPCRs do suggest modifications of the core ergot alkaloid scaffold can generate
analogs with a range of potencies and efficacy.
In conclusion, ergotamine is fortuitously suited to engage pathways in both host and parasite that
are simultaneously deleterious to the blood fluke but beneficial to the infected host in terms of
worm clearance and mitigation of damage caused by eggs. Rather than prioritizing ‘selective’
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antiparasitic therapies with no host effects, these data demonstrate merit in evaluating agents with
broader polypharmacology across parasite and host as a route to novel discovering effective treat-
ments for parasitic disease.
Materials and methods
Key resources table
Reagent type (species)
or resource Designation Source or reference Identifiers Additional information
Cell line HEK293 cells Company ATCC; CRL-1573
Biological sample
(Schistosoma mansoni)
Schistosoma
mansoni
Stock Center BEI: NR-34792 Biodefense and Emerging
Infections Research Resources
Repository (BEI Resources)
Biological sample
(Schistosoma japonicum)
Schistosoma
japonicum
Stock Center BEI: NR-45100;
BEI:NR-45101
Biodefense and Emerging
Infections Research Resources
Repository (BEI Resources)
Biological sample
(Schistosoma hematobium)
Schistosoma
hematobium
Stock Center BEI: NR-45102;
BEI:NR-45103
Biodefense and Emerging
Infections Research Resources
Repository (BEI Resources)
Recombinant DNA
reagent
Sm.5HTRL Data repository GenBank accession
KX150867
Recombinant DNA
reagent
Sj.5HTR Data repository GenBank accession
number MG813904
Recombinant DNA
reagent
Sh.5HTR Data repository GenBank accession
number MG813903
Commercial assay
or kit
GloSensor 22F cAMP
sensor
Company Promega; E2301
Commercial assay
or kit
D-luciferin sodium salt Company Gold Biotechnology;
LUCK-100
Commercial assay
or kit
Cleaved caspase  3 Company Biocare; CP-229C
Chemical compound,
drug
NCI Natural Products
Set IV
Other National Institutes of Health,
NCI Development Therapeutics
Program (DTP)
Chemical compound,
drug
Natural Product Library Company TimTec: NPL-800
Chemical compound,
drug
Natural Derivatives
Library
Company TimTec: NDL-3000
Chemical compound,
drug
LSD Other NIDA; 7315–006 National Institute on Drug
Abuse (NIDA)
Chemical compound,
drug
BOL-148 Other NIDA; 7315–010 National Institute on Drug
Abuse (NIDA)
Chemical compound,
drug
PZQ - praziquantel Company Sigma Aldrich:
P4668-1G
Chemical compound,
drug
ergotamine Company Sigma Aldrich:
1241506–150 MG
Chemical compound,
drug
dihydroergotamine Company Sigma Aldrich:
D1952000
Chemical compound,
drug
bromocriptine Company Sigma Aldrich:
B2134-100MG
Chemical compound,
drug
IBMX Company Sigma Aldrich:
I5879-100MG
Chemical compound,
drug
LAMPA Company Cerilliant: L-004–1 ML
Chemical compound,
drug
Lisuride Company Tocris: 4052
Continued on next page
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Continued
Reagent type (species)
or resource Designation Source or reference Identifiers Additional information
Chemical compound,
drug
dihydroergotoxine Company Tocris: 0474
Chemical compound,
drug
methylergometrine Company Tocris: 0549
Chemical compound,
drug
forskolin Company Cell Signaling
Technology: 3828
Software, algorithm HISAT2 PMID: 25751142
Software, algorithm edgeR PMID: 19910308
Software, algorithm Ingenuity Pathway
Analysis
Company QIAGEN Bioinformatics:
IPA
Software, algorithm DAVID Bioinformatics
Resources 6.8
Other Laboratory of Human
Retrovirology and
Immunoinformatics (LHRI)
Molecular cloning
The sequence for Sm.5HTRL (GenBank accession KX150867 [Chan et al., 2016a]) was used to BLAST
the S. haematobium and S. japonicum genomes for putative homologs. The resulting S. haema-
tobium (NCBI Reference Sequence XM_012944163 and XM_012944164) and S. japonicum (GenBank
FN332592.1) hits were used as templates to clone out full-length mRNA sequences by 5’ and 3’
RACE (Marathon cDNA Amplification Kit, Clontech) using S. haematobium and S. japonicum total
RNA provided by the Schistosomiasis Resource Center. Finalized sequences have been deposited
with NCBI (Sh.5HTR = GenBank accession number MG813903, Sj.5HTR = GenBank accession num-
ber MG813904). Plasmids for heterologous expression were generated by codon optimization of the
coding sequence for mammalian expression and subcloning into either pcDNA3.1(-) (between NotI
and EcoRI) or pEGFP-N3 (EcoRI).
Cell lines and culture
HEK293 cells (ATCC CRL-1573, an authenticated cell line validated by STR profiling) were cultured in
growth media consisting of DMEM supplemented with GlutaMAX (Gibco cat # 10566016) + 10%
heat inactivated fetal bovine serum and penicillin-streptomycin (100 units/mL, ThermoFisher). Stable
cell lines for the pGloSensor-22F cAMP Plasmid (Promega) and schistosome 5HTRs in pcDNA3.1(-)
were selected with hygromycin (200 mg/mL) and G418 (400 mg/mL). The correct identity of each sta-
bly expressed sequence was verified by isolating total RNA from each stable line (TRIzol Reagent,
Ambion) and amplifying the sequence of interest with gene specific primers flanking the 5’ and 3’
regions of the coding sequence (SuperScript III One-Step RT-PCR System, Invitrogen). PCR products
were ligated into a TA cloning vector (pGEM-T Easy, Promega) and verified by Sanger sequencing.
cAMP luminescence assays
HEK293 lines stably expressing both the GloSensor 22F cAMP sensor and Sm.5HTRL were cultured
in growth media supplemented with 10% dialyzed FBS. For cAMP assays in 96 well format, cells cul-
tured in T-75 flasks were trypsinized (TrypLE Express, Gibco) and plated in solid white 96 well plates
(Costar cat # 3917) the day prior to assay at a density of 2.5  104 cells/well. The following day
media was removed and replaced with assay buffer consisting of HBSS buffered with HEPES (20
mM, pH 7.4) + BSA (0.1% w/v) and D-luciferin sodium salt (1 mg/mL, Gold Biotechnology). Plates
were equilibrated at room temperature for 1 hr, at which point 3-Isobutyl-1-methylxanthine (IBMX
200 mM, Sigma Aldrich) was added. Plates were equilibrated a further 30 min prior to test compound
addition. Test compounds were added and luminescence was read for 45 min on a GloMax-Multi
Detection System plate reader (Promega) to screen for agonists, after which plates were removed,
5-HT was added to each well at a concentration determined to achieve a maximal response for each
stable cell line (Sm.5HTRL = 500 nM, Sj.5HTR = 500 nM, Sh.5HTR = 60 nM), and plates were read a
second time to screen for antagonist activity. Readings performed in 384 well format were modified
so that cells were assayed in suspension. Cells were grown to 70% confluence in T-75 flasks,
Chan et al. eLife 2018;7:e35755. DOI: https://doi.org/10.7554/eLife.35755 18 of 25
Research article Cell Biology Microbiology and Infectious Disease
trypsinized and pelleted (300 RCF x 5 min). Media was removed and cells were resuspended in 25
mL assay buffer supplemented with IBMX (200 mM). A 96 channel semi-automated pipet (Eppendorf
epMotion 96) delivered 55 mL of cell suspension per well (5000 cells/well) into solid white 384 plates
(Corning 3574). After one hour of equilibration, test compounds were screened at a fixed concentra-
tion of 10 mM, and control wells (64 wells per plate) were treated with vehicle alone (1% DMSO in
HBSS), providing an internal negative control reference. Following 60 min incubation at ambient
temperature, plates were read for agonist activity, defined as a >10 fold increase in luminescence
relative to control, DMSO treated wells on the same plate. Serotonin (1 mM) was then added to each
well, and after 60 min the plate was read again to identify compounds with antagonist activity,
defined as compounds that inhibiting 5-HT evoked signal by >90% relative to control wells. The ini-
tial high-throughput screen in 384 well format was performed as a single replicate, with all ‘hits’
meeting agonist or antagonist thresholds re-screened in 96 well format (technical quadruplicates
performed for three biological replicates). Counter screening of primary hits against the parental
HEK293 cell line expressing the GloSensor 22F cAMP sensor and lacking Sm.5HTRL was performed
to eliminate compounds stimulating cAMP (>3 fold change in basal luminescence) or inhibiting for-
skolin evoked cAMP production (>25% inhibition relative to DMSO controls).
Reagents and chemicals
A complete list of chemical vendors, catalog numbers and SMILES is contained in
Supplementary file 1. Natural product libraries were sourced from the National Institutes of Health
(NCI Natural Products Set IV) and TimTec (Natural Product Library [NPL-800] and Natural Derivatives
Library [NDL-3000]). LSD and BOL-148 were sourced from the National Institute on Drug Abuse
(NIDA). The following compounds were sourced from Sigma Aldrich: praziquantel (PZQ, P4668-1G),
ergotamine tartrate (1241506–150 MG), dihydroergotamine tartrate (D1952000), bromocriptine
(B2134-100MG). LAMPA was sourced from Cerilliant (L-004–1 ML). Lisuride maleate (4052), dihy-
droergotoxine mesylate (0474) and methylergometrine maleate (0549) were sourced from Tocris.
Ethics statement
All animal experiments followed ethical regulations approved by the Medical College of Wisconsin
and Iowa State IACUC committees and additionally reviewed in the context of funding by the
National Institutes of Health (NIAID).
Ex vivo schistosome assays
Female Swiss Webster mice infected with S. mansoni cercariae (NMRI strain) were sacrificed 49 days
post infection by CO2 euthanasia. Adult schistosomes were recovered by dissection of the mesen-
teric vasculature. Harvested schistosomes were washed in RPMI 1640 Medium with GlutaMAX + 5%
heat inactivated FBS (Gibco) and Penicillin-Streptomycin (100 units/mL).
For movement assays, worms were cultured 37˚C and 5% CO2 in vented 100  25 mm petri
dishes (ThermoFisher cat # 4031) containing 50 mL of media and used 1–3 days after harvesting.
Prior to assessing worm movement, male worms were transferred to a six well dish (4–5 individual
worms per well) containing 3 mL drug solution in RPMI 1640 supplemented with HEPES (25 mM)
and FBS (5%). Videos were recorded using a Zeiss Discovery v20 stereomicroscope and a QiCAM
12-bit cooled color CCD camera controlled by Metamorph imaging software (version 7.8.1.0). 1 min
recordings were acquired at 4 frames per second, saved as a. TIFF stack, and movement was ana-
lyzed using ImageJ software as described in (Chan et al., 2016a, 2016b). Data represents
mean ± standard error for 3 independent experiments. EC50 and IC50 values are reported ± 95%
confidence interval of fitted curves.
For egg laying assays, adult schistosomes were transferred to 24 well plates the day after harvest-
ing from mice (5 pairs of male and female worms in 2 mL media/well). Eggs were counted daily using
a stereomicroscope, after which worms were transferred to a new well with fresh drug-containing
media. Egg counts were recorded for 5 days, and data processed as the mean number of eggs laid
per worm pair per day. Measurements of egg dimensions were quantified using the ‘analyze>meas-
ure’ function in ImageJ to record the length and width of individual eggs.
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In vivo schistosome drug screening
Female Swiss Webster mice were exposed to 200 s. mansoni cercariae (NMRI strain) at between 4–6
weeks old. For hepatic shift assays, infections matured to 7 weeks, at which point mice were given
test compounds by intraperitoneal injection and euthanized 3 hr later. Compounds were solubilized
in 50 mL DMSO, and diluted in 200 mL 5% w/v Trappsol (Cyclodextrin Technologies Development,
THPB-p-31g) in saline (NaCl 0.9%) solution. Immediately after being euthanized, mice were dissected
to separate the liver from the portal vein, so that the number of worms recovered from the portal
vein, mesenteric vasculature and liver could be recorded for each mouse. Hepatic shift assays were
performed on at least 3 mice per drug treatment. Assays testing the curative efficacy of compounds
against schistosome infections were performed on mice at 3 weeks post infection (immature para-
sites) and 6 weeks post infection (mature parasites). Drugs were dosed as follows. Ergotamine (60
mg/kg) was solubilized in 50 mL DMSO and diluted in 200 mL Trappsol-saline and delivered by intra-
peritoneal injection twice a day for one week. Praziquantel (50 mg/kg) was similarly solubilized and
injected intraperitoneally once a day for one week. The negative control cohort was given twice daily
injections of DMSO (50 mL) added to 200 mL Trappsol-saline solution. Mice were weighed and eutha-
nized at 49 days post infection. Worms were harvested and counted as described for the hepatic
shift assay. Spleen and livers were weighed, and a segment of intestine was excised from the most
distal region of the rectum to 10 cm above the cecum. The small and large intestines were separated
by cutting immediately above and below the cecum. Each was cut lengthwise to expose the lumen
and thoroughly washed in NaCl (1.2%) to remove excrement. Intestines were laid flat with the intesti-
nal mucosa facing upwards and clamped between two glass plates to allow visual inspection of egg
morphology and number using a stereo microscope. Scored egg counts reflect ‘viable’ eggs contain-
ing a developing embryo or a mature miracidium, while empty egg shells and granulomas were not
included (Pellegrino and Faria, 1965; Mati and Melo, 2013).
Liver histology and immunohistochemistry
Mouse livers were removed immediately after animals were euthanized, rinsed in ice cold PBS, and
fixed in 10% neutral buffered formalin. For H and E stain, Movat’s stain, Masson’s trichrome, and
aldehyde fuchsin staining, samples were embedded in paraffin and sectioned at 4 microns (Microm
HM355S). For Oil red staining, livers were equilibrated in freezing medium (10% w/v and then 30%
w/v sucrose solution in PBS) prior to cryosectioning (Leica CM1850 UV Cryostat). If paraffin embed-
ded, slides were deparaffinized, hydrated, and the following staining procedures were then per-
formed: H and E stain, slides were stained with Harris hematoxylin and eosin working solution (Poly
Scientific). Movat’s stain, Alcian blue (1% w/v), hematoxylin (10%), crocein scarlet –acid fuchsin solu-
tion, and alcoholic saffron (6.5% w/v). Masson’s trichrome, slides were pre-treated with Bouin’s solu-
tion and successively stained with hematoxylin, Biebrich-Scarlet-Acid Fuchsin and Aniline Blue
solution. Aldehyde Fuchsin. slides were stained with aldehyde fuchsin and counterstained with fast
green. Oil red O staining, after cryosectioning onto Superfrost slides (Fisherbrand), samples were
stained with Oil Red (0.3% w/v in 60% isopropanol) followed by hematoxylin counterstain. Cleaved
Caspase-3 staining, slides were treated with Leica BOND Epitope Retrieval Solution 2 (20 min), per-
oxidase-blocking solution (Dako), avidin/biotin blocking kit (Vecgtor) and background sniper block-
ing reagent (Biocare) per manufacturer’s instructions. This was followed by Cleaved Caspase-3
primary antibody incubation (Biocare, CP-229C) at 1:100 dilution for 90 min at room temperature, 3
 1 min washes (Lieca BondTM Wash Solution), and incubation in biotinylated secondary antibody
(Jackson Immuno, 771-066-152) at 1:500 dilution for 30 min, 3  1 min washes, and finally incubation
in Streptavidin HRP (Dako, P0397) at 1:300 dilution. After washing (3  1 min), staining was visual-
ized using DAB + Substrate Chromogen System (Dako, K3468). As a negative control, samples were
treated as stated above but without primary antibody.
Transcriptome sequencing
Mice were infected and treated with drugs as described above. After drug treatment from weeks 6–
7 post infection, mice were euthanized and livers and spleens were immediately removed and placed
on ice. For liver samples, a section of the larger, right lobe was excised and homogenized in TRIzol
Reagent (Invitrogen). For spleen samples, the entire organ was homogenized in TRIzol. Samples
were stored in  80˚C until processed. Total RNA was extracted from TRIzol according to
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manufacturer’s protocols and quantified with RiboGreen RNA Assay Kit. Libraries were generated
using the Clontech StrandedRNA Pico Mammalian kit and sequenced using the Illumina HiSeq 2500
system (high-output mode, 50 bp paired-end reads) at a depth of approximately 20 million reads/
sample. Trimmed reads were mapped to the mouse genome (mm10/GRCm38) using HISAT2.
Expression was quantified using featureCounts (read counts) and cuffquant (FPKM). EdgeR was used
to identify differentially expressed genes (tagwise dispersion model, adjusted p-value<0.05) which
were processed using Ingenuity Pathway Analysis (Qiagen) and DAVID functional annotation tool
(version 6.8). RNA-Seq data has been deposited in the NCBI SRA database under accession number
SRP131511.
Statistics
Metrics for evaluating cell based screening assays include coefficient of variation (CV%), signal win-
dow (SW), Z factor and Z’ factor. Equations for each metric are included in the legend of Figure 1—
figure supplement 3. Sample sizes for in vivo mouse experiments measuring worm burden were
chosen to exceed minimum sample sizes determined by power calculations assuming a difference in
means of 60%, standard deviation of 20%, power of 0.9 (b = 0.1) and significance criterion (a) of
0.05. Sample size for in vivo mouse survival analysis experiments also assumed a significance crite-
rion (a) of 0.05 and power of 0.9 (b = 0.1), with half of the mice being treated with experimental
drug and half with vehicle control and a hazard ratio of 5. RNA-Seq data was analyzed for differential
expression in EdgeR which generated FDR adjusted p-values using the Benjamini-Hochberg method
- transcripts with p-values under 0.05 were considered differentially expressed.
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